Veridix AI, part of Emmes Group, a dedicated technology CRO (contract research organization) powered by artificial intelligence, announced the launch of new protocol digitization capabilities. This advanced tool lays the foundation for speeding up the clinical trial design process by up to 30%.
The new concept, created within Veridix AI’s unified eClinical platform called Advantage eClinical Cloud, uses natural language processing (NLP) techniques combined with artificial intelligence to digitize clinical assessment protocols into structured data elements such as visit schedules, cohorts and eCRF. It has been trained and optimized using existing data from clinical trials, enables automated generation of visit schedules, and provides a list of predicted eCRFs with over 82% accuracy.
Until now, clinical trial processes have been burdened by slow, manual, error-prone processes. One of them is also the assessment of the protocol to determine the elements needed for the construction of the study. The new concept therefore brings concrete application of artificial intelligence techniques to speed up clinical trials and improve data quality.
Also Read: Persist AI & Nivagen Partner on AI for Injectable Manufacturing
“The digitization of protocols has the potential to change the way information from protocols is used throughout the clinical trial process and ecosystem. Thanks to NLP and AI technologies, we automate other parts of the clinical evaluation process. This is just one example of how we are incorporating more technology and AI into the clinical research process,” said Rama Kondru, CEO of Veridix AI.
Upcoming versions of the Advantage eClinical Cloud platform will offer an integrated workflow for transforming protocols into structured data elements, and eventually automated eCRF creation and associated edit review based on AI predictions.
“This unique feature helps us speed up the study build process and allows our data managers to focus on value-added work instead of manual, time-consuming processes,” said Emmes Group CEO Sastry Chilukuri. “We are already deploying this feature in over 40 new studies in our government and commercial portfolio,” added Chilukuri. “This underscores our commitment to improving clinical trials by leveraging next-generation technologies and artificial intelligence capabilities.”
Source: PRNewswire
